Lifastuzumab vedotin

Synonyms: LIFA, DNIB0600A, RG-7599

Catalog No.D4010 Purity:99%

Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin is used in the treatment of platinum-resistant ovarian cancer.

CAS No. 1401812-88-1

Click to purchase products related to Lifastuzumab vedotin

Purity & Quality Control

Batch: D401001 Purity: 99% Protein concentration: 8.79mg/ml Endotoxin Level: ＜1EU/mg

Choose Selective Sodium Channel Inhibitors

Name	Citation	Sodium Channel
A-803467	2	++++
Camostat Mesilate	14	+++
Ambroxol HCl	0	+++
Benzocaine	✔
Tolperisone HCl	✔
Vinpocetine	✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin is used in the treatment of platinum-resistant ovarian cancer.

References
[1] Banerjee S, et al. Ann Oncol. 2018;29(4):917-923.

References

[1] Banerjee S, et al. Ann Oncol. 2018;29(4):917-923.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1401812-88-1
ADC antiody	Lifastuzumab
ADC cytotoxin	MMAE
Formulation	0.1 MPro-Ac，0.02 MArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.